Genomic alterations in biliary tract cancer predict prognosis and immunotherapy outcomes

BACKGROUND: Recently, immunotherapy with immune checkpoint inhibitors (ICIs) has shown promising efficacy in biliary tract cancer (BTC), which includes gallbladder cancer (GBC) and cholangiocarcinoma (CHOL). Understanding the association between immunotherapy outcomes and the genomic profile of adva...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Xiaofeng, Wang, Deqiang, Liu, Jing, Qiu, Jingrong, Zhou, Jun, Ying, Jieer, Shi, Yan, Wang, Zhaoxia, Lou, Haizhou, Cui, Jiuwei, Zhang, Jingdong, Liu, Yunpeng, Zhao, Fengjiao, Pan, Lanlan, Zhao, Jianyi, Zhu, Dongqin, Chen, Shiqing, Li, Xiangcheng, Li, Xue, Zhu, Liuqing, Shao, Yang, Shu, Yongqian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Immunotherapy Biomarkers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8603283/
https://www.ncbi.nlm.nih.gov/pubmed/34795005
http://dx.doi.org/10.1136/jitc-2021-003214

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8603283/
https://www.ncbi.nlm.nih.gov/pubmed/34795005
http://dx.doi.org/10.1136/jitc-2021-003214

Ejemplares similares